Navigation Links
Penn researchers show single drug and soft environment can increase platelet production

PHILADELPHIA Humans produce billions of clot-forming platelets every day, but there are times when there aren't enough of them, such as with certain diseases or during invasive surgery. Now, University of Pennsylvania researchers have demonstrated that a single drug can induce bone marrow cells called megakaryocytes to quadruple the number of platelets they produce.

Jae-Won Shin, a graduate student of pharmacology in Penn's Perelman School of Medicine, and Dennis E. Discher, professor in the Department of Chemical and Biomolecular Engineering in the School of Engineering and Applied Science, led the research. They collaborated with Joe Swift and Ph.D. student Kyle R. Spinler, also of Chemical and Biomolecular Engineering.

Their research was published in the journal Proceedings of the National Academy of Sciences.

Megakaryocytes are the large bone marrow cells that produce platelets, the smaller cell fragments that form clots to seal blood vessels when the vessels are damaged. The amount of platelets they produce relates to their size. Unlike most other cells, when megakaryocytes copy their DNA, they don't split into two cells but continue to grow larger.

"These cells take the relatively unusual step of becoming bigger and bigger, adding multiple nuclei, which you don't see with other cell types," Discher said. "Mature, multinucleated megakaryocytes are better than uni- or bi-nucleated ones; they have more mass and are ready to make more platelets."

When mature, the megakaryocyte will extend a tendril into a neighboring blood vessel; the flow of blood pulls off pieces of the cell, forming platelets. The motor protein myosin-II plays a number of roles in this process; by inhibiting it with a drug known as belebbistatin, the researchers caused megakaryocytes to make up to four times as many platelets as when it is active.

Myosin-II is responsible for many body systems that require contractile tension, such as flexing one's muscles. In many cells, it is responsible for the integrity of the outer membranes, for cell division and for key aspects of adhesion. Because megakaryocytes are best when they are large, multi-nucleated and fragment easily, inhibiting myosin-II helps produce more platelets in three distinct ways.

"The first factor is when cells normally divide, there is a contracting force between the dividing cells that cleave them apart," Shin said. "But if you inhibit myosin, there is no contracting force and cells grow without dividing. That's how they become multi-nucleated and how the cell mass becomes bigger.

"The second factor is cytoskeletal stiffness and tension in the cell. When myosin is active, the cell is stiff and tense like well-toned muscle, but if you inhibit the myosin, the cell becomes flaccid and more easy to push around and fragment," he said.

"The third factor is that cells are able to sense the stiffness of their microscopic environment and react to it, which is also regulated by cellular contractivity," Shin said. "Adhering to bone inhibits megakaryocyte growth; without myosin-II, they grow as if they were adhering to something soft."

By testing the megakaryocytes' growth in different cell culture dishes and gels, the researchers were also able to show that a soft matrix, similar to squishy bone marrow, induced more platelet production than a rigid matrix.

After growing the platelets in Petri dishes saturated with the myosin-II inhibitor blebbistatin, the megakaryocytes were soft enough to spontaneously fragment into platelets. Because platelets need functioning myosin-II to form rigid clots, the researchers subsequently washed away the drug to show that the platelets could still activate.

While the researchers also transplanted blebbistatin-treated human megakaryocytes into genetically modified mice to show that they maintained their increased platelet production within living systems, most of their work was done in vitro to demonstrate that platelets could be successfully synthesized in a lab.

"Platelet transfusions are harder and harder to come by. Not only are there contamination issues, but platelets are also very short-lived," Shin said. "They only last about a week in a transfusion bag. The ability to make them in large quantities could save lives."


Contact: Evan Lerner
University of Pennsylvania

Related biology technology :

1. SANYO and BD Biosciences Collaborate to Offer Researchers Valuable Technology and Research Tools
2. TUM researchers develop environmentally friendly process to improve storage stability of probiotics
3. Researchers image graphene electron clouds, revealing how folds can harm conductivity
4. Researchers clarify properties of confined water within single-walled carbon nanotube pores
5. Researchers engineer the environment for stem cell development to control differentiation
6. Penn researchers break light-matter coupling strength limit in nanoscale semiconductors
7. Researchers From More Than 30 Countries Share Findings About the Use of Ultrasound in the Prevention, Diagnosis and Treatment of Heart Disease
8. Singapore researchers invent broadband graphene polarizer
9. Livermore researchers develop battery-less chemical detector
10. Researchers create terahertz invisibility cloak
11. UCLA researchers now 1 step closer to controlled engineering of nanocatalysts
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:6/9/2016)... an innovation leader in attendance control systems is proud to announce the introduction of ... make sure the right employees are actually signing in, and to even control the ... ... ... ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... ...
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
Breaking Biology News(10 mins):